Is Medicamen Organ. overvalued or undervalued?

As of 4 November 2025, Medicamen Organ. has moved from a fair to an expensive valuation grade. The company is currently considered overvalued based on its financial ratios and peer comparisons. Key ratios include a PE Ratio of 11.91, an EV to EBIT of 9.94, and a Price to Book Value of 1.34, which do not justify its current market price. In comparison to its peers, Medicamen Organ. stands out as overvalued. For instance, Sun Pharma has a significantly higher PE Ratio of 35.41, while Cipla, which is rated attractive, has a PE Ratio of 22.35. Furthermore, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -38.22% compared to the Sensex's 8.26%. This underperformance reinforces the notion that Medicamen Organ. is not a favorable investment at its current valuation.